Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
Puma Biotechnology (PBYI) Stock Price & Analysis
582 Followers
PBYI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.13 - $7.73
Previous Close$3.66
Volume250.25K
Average Volume (3M)471.78K
Market Cap
$176.55M
Enterprise Value$180.13M
Total Cash (Recent Filing)$107.16M
Total Debt (Recent Filing)$110.73M
Price to Earnings (P/E)11.4
Beta1.20
Next Earnings
Aug 01, 2024EPS Estimate
-$0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.32
Shares Outstanding48,238,850
10 Day Avg. Volume298,772
30 Day Avg. Volume471,782
Standard Deviation0.24
R-Squared0.05
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-19.42
Price to Sales (P/S)0.61
Price to Cash Flow (P/CF)3.50
P/FCF Ratio2.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.79
Enterprise Value/Gross Profit1.04
Enterprise Value/Ebitda8.70
Forecast
1Y Price Target
$4.33Price Target Upside18.31% Upside
Rating ConsensusHold
Number of Analyst Covering3
Puma Biotechnology News
PremiumCompany Announcements
Puma Biotechnology Stockholders Elect Leadership and Approve Amendments
Bulls Say, Bears Say
Bulls Say
Clinical TrialPositive alisertib data in advanced EGFR-mutated NSCLC TP53 wild-type patients.
Financial Performance1Q24 results showed revenue and non-GAAP EPS above estimates.
Legal VictoryPatent infringement win could reap financial benefits for Puma.
Bears Say
Adverse EventsThe most common Grade ≥3 AEs in the alisertib alone arm were neutropenia at 43.4%, leukopenia at 17.4%, and anemia at 19.6%.
Sales Performance1Q24 U.S. Nerlynx sales were down year over year and quarter over quarter.
Side EffectsThe most common treatment-related adverse events of any grade included neutropenia at 42.9%, anemia at 42.9%, diarrhea at 38.1%, and lymphopenia at 33.3%.
---
Ownership Overview
37.83% Insiders
10.84% Mutual Funds
9.80% Other Institutional Investors
41.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $2.13 and its highest was $7.73 in the past 12 months.
What is Puma Biotechnology’s market cap?
Currently, no data Available
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on May 02, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.217 by $0.117.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Undervalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is -$0.05.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 48,238,850 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.217. Following the earnings report the stock price went down -2.016%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Among the largest hedge funds holding Puma Biotechnology’s share is EntryPoint Capital, LLC. It holds Puma Biotechnology’s shares valued at 329K.
---
Puma Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.33 (18.31% Upside)
$4.33 (18.31% Upside)
Blogger Sentiment
Bullish
PBYI Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 73.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.58%
12-Months-Change
Fundamentals
Return on Equity
40.02%
Trailing 12-Months
Asset Growth
9.12%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
---
PBYI Company Deck
---
PBYI Earnings Call
Q1 2024
0:00 / 0:00
---
PBYI Stock 12 Month Forecast
Average Price Target
$4.33
▲(18.31% Upside)
Technical Analysis
Best Analysts Covering PBYI
1 Year
1 Year Success Rate
17/26 ratings generated profit
1 Year Average Return
+6.88%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 65.38% of your transactions generating a profit, with an average return of +6.88% per trade.
---